Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. It has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.
종목 코드 EVOK
회사 이름Evoke Pharma Inc
상장일Sep 25, 2013
CEOMr. Matthew J. (Matt) D'Onofrio
직원 수3
유형Ordinary Share
회계 연도 종료Sep 25
주소420 Stevens Avenue
도시SOLANA BEACH
증권 거래소London Stock Exchange
국가United States of America
우편 번호92075
전화18583451494
웹사이트https://evokepharma.com/
종목 코드 EVOK
상장일Sep 25, 2013
CEOMr. Matthew J. (Matt) D'Onofrio
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음